{
  "id": 3234,
  "text": "1171.Duenas-Gonzalez, A., et al.Concomitant chemoradiation versus neoadjuvant chemotherapy in locally advanced cervical carcinoma: results from two consecutive phase II studies.Ann Oncol 13, 1212-1219 (2002).",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: 1171.Duenas-Gonzalez, A., et al.Concomitant chemoradiation versus neoadjuvant chemotherapy in locally advanced cervical carcinoma: results from two consecutive phase II studies.Ann Oncol 13, 1212-1219 (2002).\n\n<question>: \n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n",
  "ChatGPT_response_0": "在治疗局部晚期宫颈癌患者时，同步放化疗和新辅助化疗是两种常见的治疗策略。同步放化疗通常被认为是标准治疗方案，适用于大多数局部晚期宫颈癌病例。它结合了放疗和化疗的协同作用，能够更有效地控制局部肿瘤，改善患者的总体生存率。\n\n然而，新辅助化疗也是一种可考虑的选择。在某些情况下，如具有特定肿瘤特征或治疗目标的患者，可能会使用新辅助化疗。它通常在放疗之前进行，以缩小肿瘤体积，从而使后续的放疗更加有效。\n\n选择何种治疗方案应根据患者的具体病情、肿瘤特征以及患者的身体状况进行。临床医师会根据现有的研究数据和患者的个体情况，为患者制定最合适的治疗计划。与医生详细讨论后，患者可以得到针对性的治疗建议。",
  "query": "根据提供的<text>，内容与宫颈癌相关。\n\n<question>: 局部晚期宫颈癌患者在治疗时，应如何选择同步放化疗还是新辅助化疗？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 根据提供的<text>，内容与宫颈癌相关。\n\n<question>: 局部晚期宫颈癌患者在治疗时，应如何选择同步放化疗还是新辅助化疗？\n\n<reference text>: 1171.Duenas-Gonzalez, A., et al.Concomitant chemoradiation versus neoadjuvant chemotherapy in locally advanced cervical carcinoma: results from two consecutive phase II studies.Ann Oncol 13, 1212-1219 (2002).\n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n\n<reply>: ",
  "response": "在治疗局部晚期宫颈癌患者时，同步放化疗和新辅助化疗是两种常见的治疗策略。同步放化疗通常被认为是标准治疗方案，适用于大多数局部晚期宫颈癌病例。它结合了放疗和化疗的协同作用，能够更有效地控制局部肿瘤，改善患者的总体生存率。\n\n然而，新辅助化疗也是一种可考虑的选择。在某些情况下，如具有特定肿瘤特征或治疗目标的患者，可能会使用新辅助化疗。它通常在放疗之前进行，以缩小肿瘤体积，从而使后续的放疗更加有效。\n\n选择何种治疗方案应根据患者的具体病情、肿瘤特征以及患者的身体状况进行。临床医师会根据现有的研究数据和患者的个体情况，为患者制定最合适的治疗计划。与医生详细讨论后，患者可以得到针对性的治疗建议。"
}